Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
High Blood Press Cardiovasc Prev. 2024 Mar;31(2):215-219. doi: 10.1007/s40292-024-00624-6. Epub 2024 Feb 3.
Familial hypercholesterolemia is a common genetic condition that significantly increases an individual's risk of cardiovascular events such as heart attack, stroke, and cardiac death and is a candidate for population-wide screening programs. Economic analyses of strategies to identify and treat familial hypercholesterolemia are limited by a lack of real-world cost estimates for screening services and medications for reducing cardiovascular risk in this population.
We estimated the cost of lipid panel testing in patients with hyperlipidemia and the cost of statins, ezetimibe, and PCKS9 inhibitors in patients with familial hypercholesterolemia from a commercial claims database and report costs and charges per panel and prescription by days' supply.
The mean cost for a 90-day supply for statins was $183.33, 2.3 times the mean cost for a 30-day supply at $79.35. PCSK9 inhibitors generated the highest mean costs among medications used by patients with familial hypercholesterolemia.
Lipid testing and lipid-lowering medications for cardiovascular disease prevention generate substantial real-world costs which can be used to improve cost-effectiveness models of familial hypercholesterolemia screening and care management.
家族性高胆固醇血症是一种常见的遗传疾病，会显著增加个体患心血管事件（如心脏病发作、中风和心脏性死亡）的风险，因此是进行人群广泛筛查计划的候选条件。由于缺乏用于筛查服务和降低该人群心血管风险的药物的实际成本估算，因此对确定和治疗家族性高胆固醇血症的策略进行经济分析受到限制。
我们从商业索赔数据库中估计了高脂血症患者进行血脂检测的成本，以及家族性高胆固醇血症患者使用他汀类药物、依折麦布和 PCKS9 抑制剂的成本，并按天供应量报告了每个检测和处方的成本和费用。
他汀类药物 90 天供应量的平均成本为 183.33 美元，是 30 天供应量平均成本 79.35 美元的 2.3 倍。在家族性高胆固醇血症患者使用的药物中，PCSK9 抑制剂产生的平均费用最高。
用于心血管疾病预防的血脂检测和降脂药物会产生大量实际成本，可用于改善家族性高胆固醇血症筛查和护理管理的成本效益模型。
